Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts $11.94 +1.61 (+15.62%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Keros Therapeutics Earnings Summary Upcoming Earnings DateMay. 6Before Market OpensEstimatedConsensus EPS (Feb. 26) -$1.36 Actual EPS (Feb. 26) -$1.14 Beat By $0.22 Actual Revenue (Feb. 26) $3.04MKeros Therapeutics issued Q4 2024 earnings on February 26, 2025, reporting an EPS of -$1.14, which topped analysts' consensus estimates of -$1.36 by $0.22. Quarterly revenue was reported to be $3.04 million, below analyst estimates of $37.32 million. With a trailing EPS of -$5.01, Keros Therapeutics' earnings are expected to decrease next year, from ($4.74) to ($4.87) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Annual Report (10-K) Press Release (8-K)KROS Upcoming EarningsKeros Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Keros Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$1.40-$1.23-$1.30Q2 20254-$1.39-$1.02-$1.21Q3 20254-$1.37-$0.66-$1.03Q4 20254-$1.41-$0.58-$0.99FY 202515-$5.57-$3.49-$4.53Q1 20261-$0.61-$0.61-$0.61Q2 20261-$0.62-$0.62-$0.62Q3 20261-$0.62-$0.62-$0.62Q4 20261-$0.62-$0.62-$0.62FY 20264($2.47)($2.47)($2.47) Remove Ads Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/6/2025(Estimated)--------2/26/2025Q4 2024-$1.36-$1.14+$0.22-$1.14$37.32M$3.04M11/6/2024Q3 2024-$1.28-$1.41 -$0.13-$1.41-$0.39M8/7/2024Q2 2024-$1.23-$1.25 -$0.02-$1.25-$0.04M5/8/2024Q1 2024-$1.33-$1.21+$0.12-$1.21-$0.08M3/1/2024Q4 2023-$1.37-$1.34+$0.03-$1.34-$0.14M11/6/2023Q3 2023-$1.35-$1.33+$0.02-$1.33-$0.01M8/7/2023Q2 2023-$1.34-$1.27+$0.07-$1.27$0.22M-5/4/2023Q1 2023-$1.14-$1.26 -$0.12-$1.26$0.22M- Keros Therapeutics Earnings - Frequently Asked Questions When is Keros Therapeutics's earnings date? Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) reported ($1.14) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.36) by $0.22. Learn more on analysts' earnings estimate vs. KROS's actual earnings. How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $3.55 million. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.01 earnings per share over the last four quarters. What is Keros Therapeutics's EPS forecast for next year? Keros Therapeutics's earnings are expected to decrease from ($4.74) per share to ($4.87) per share in the next year. More Earnings Resources from MarketBeat Related Companies BEAM Earnings GLPG Earnings CNTA Earnings AGIO Earnings KNSA Earnings ANIP Earnings APGE Earnings JANX Earnings KYMR Earnings ARWR Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:KROS) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts